GNI Group Ltd
TSE:2160
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 544
3 805
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
GNI Group Ltd
GNI Group Ltd
Total Liabilities & Equity
GNI Group Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GNI Group Ltd
TSE:2160
|
Total Liabilities & Equity
¥69B
|
CAGR 3-Years
34%
|
CAGR 5-Years
29%
|
CAGR 10-Years
27%
|
|
|
PeptiDream Inc
TSE:4587
|
Total Liabilities & Equity
¥93.4B
|
CAGR 3-Years
50%
|
CAGR 5-Years
38%
|
CAGR 10-Years
32%
|
|
|
Takara Bio Inc
TSE:4974
|
Total Liabilities & Equity
¥121.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Total Liabilities & Equity
¥36.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
33%
|
CAGR 10-Years
25%
|
|
|
S
|
StemRIM Inc
TSE:4599
|
Total Liabilities & Equity
¥9.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Total Liabilities & Equity
¥6.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
Glance View
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
See Also
What is GNI Group Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
69B
JPY
Based on the financial report for Jun 30, 2024, GNI Group Ltd's Total Liabilities & Equity amounts to 69B JPY.
What is GNI Group Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
27%
Over the last year, the Total Liabilities & Equity growth was 53%. The average annual Total Liabilities & Equity growth rates for GNI Group Ltd have been 34% over the past three years , 29% over the past five years , and 27% over the past ten years .
You don't have any saved screeners yet
